Biotech Faces a Real Estate Shortage
In this episode of the Dave & Dave podcast, we learn about the real estate shortage in the nation’s biotech hubs, the challenges of obtaining and creating new space, how early-stage companies are coping, and what’s on the drawing board to help alleviate the shortage.
Dave Plaskow: Hello, and welcome to EisnerAmper’s technology podcast series. With more than 500 hundred technology clients, we’re always interested in the latest industry trends and developments, as well as any related business and accounting opportunities and challenges. This time, we’re turning our attention to the biotech sector, specifically, the challenge of biotechs finding available real estate. I’m your host, Dave Plaskow, and with us today is Dave Katz, Senior Manager in EisnerAmper’s Technology and Life Sciences Practice. We like to call this the Dave & Dave show. Dave, welcome, and thanks for being here.
Dave Katz: Thanks Dave.
DP: So Dave, give us the lay of the land, so to speak, when it comes to biotech real estate.
DK: Well, there’s good news and there’s bad news. Good news is there’s never been a better time to be in the biotech sector, but the bad news is there’s simply not enough workspace to meet the demand. If you look at the biotech hubs such as San Francisco, Boston, New York, you’ll find extremely limited vacancies – somewhere in the 1% to 3% – sky-high prices, design issues for expanding or creating a biotech structure. That makes it challenging for larger firms to secure space and nearly impossible for startups to put a roof over their heads.
DP: What kind of sky-high prices are we talking about?
DK: If you look Cambridge, just over the river from Boston, rents are in the $70 to $80 per square foot range and increasing at a rate of 10% to 15% annually. Prices for Kendall Square’s Lab Central incubator, which is in the heart of Boston’s biotech sector, start at $400 per month for membership, $3,800 per month for a bench spot, and $430 to $535 per month for a lab desk. Private suites costs $16,000 to $18,000 per month, and additional office space is somewhere in the $1000 to $3000 per month range, and that’s a lot of money and tall prices for early bio stage companies.
DP:So instead of renting, why not just build more incubators or maybe look at some commercial real estate and just retrofit that?
DK: Yes, it’s a good question. So, biotech has very specific requirements as to water systems, fire suppression systems, HVAC, electrical systems. In addition, the local permit process can be lengthy and expensive. That’s why improvements cost in the $200 per square foot range, and new construction could be upwards of $600 per square foot.
DP:The numbers are pretty daunting. So what does that mean for the small, early stage startups?
DK: Many are fleeing to the suburbs. You go to Boston, they’re going to Watertown; you go to San Fran, they’re going to the Peninsula or East Bay or Marin County; New York to Westchester or to New Jersey; and in these suburbs, commercial real estate is plentiful post-great recession, costs are significantly less. There’s also biotech space available at former pharma locations like Roche in northern New Jersey. So small companies are increasingly using virtual biotech, being based in an urban hub but outsourcing the lab work to research organizations located elsewhere.
DP:That all sounds good, but I’m assuming that nothing beats being centrally located in a big city.
DK: That’s right. There’s really no substitute for being in a downtown life science community with easy access to funding, service providers, research institutions, hospitals, universities and a broadly talented work base, and politicians in these cities are also starting to gain a better understanding of the value of becoming a biotech hub.
DP: Any major construction on the drawing board?
DK: Officials in New York are interested in putting life science facilities on Roosevelt Island and near Bellevue Hospital. A relatively new incubator, Harlem Biospace, offers workspace to early stage companies for about $1,000 per month, and the Alexandria Center is undergoing significant expansion with its LaunchLabs to help offer affordable space for seed-stage companies with rents in the $2,000 per month. LaunchLabs hopes to open in 2017. And then you have BioBAT at the Brooklyn Army Terminal, which offers 500,000 square feet of space. So, thus far, most takers have been mature and mid-stage companies, but we might see some early stage companies get in there as well. In San Fran, the Cove at Oyster Point will bring an additional 1 million square feet of biospace to the city when complete in 2017. Also, Genesis Towers in South San Fran will add more than 800,000 square feet by early 2018. We may also see the continued development of up-and-coming biotech hubs like Seattle and Texas, so these developments are encouraging.
DP:You’re a business advisor, you’re out at clients, on the frontlines so to speak. Where do you fit into all this? Where can you help these companies that are looking to efficiently and price-effectively obtain real estate?
DK: So there’s ample opportunities, whether it’s performing cost segregation studies, due diligence, calculating NOLs or forensic accounting. We can help mitigate some of the sticker shock for life science companies looking to expand or acquire space.
DP:Well Dave, thanks as always for your expertise and your insight.
DK: Thanks Dave.
DP:And thank you for listening to the Dave & Dave Show, as part of the EisnerAmper podcast series. Visit EisnerAmper.com for more information on this, and a host of other topics, and join us for our next EisnerAmper podcast when we get down to business.
In this episode of the Dave & Dave Show, we look at New York City’s proposed annual cap on the number of ride-sharing vehicles, such as Uber and Lyft, and the larger implications for this unique urban initiative.
Cryptocurrency still has the reputation for significant price swings. In this episode of the Dave & Dave Show, we look at a new contender—with some big backers—that’s tied to the U.S. dollar to help temper that volatility.
The Dave & Dave Show takes a look at a tech startup, Aerobotics, that is using drones to help farmers in South Africa.
In this episode of the Dave and Dave show, we look at a 3D-printed housing community for needy families in El Salvador, the goals are, some of the attached business issues, and how this could be a technological game-changer for affordable housing.
The Dave and Dave Show looks at 23andMe’s DNA test-taking kit, its recent approval by the FDA to scan for certain breast cancer genes, where the market is headed, and what it means for the biotech industry and its business advisors.
The “Dave & Dave Show” examines a few interesting things Amazon is up to on its march toward global e-tail domination, such as its choosing a city for its new headquarters, its foray into health care, Amazon Go and more.
This episode of “The Dave & Dave Show” covers a unique, FDA-approved EKG device for the Apple Watch. We’ll discuss the science and the business behind this promising new technology, as well as how the market for smart watches is doing.
In this final Dave & Dave podcast of 2017, we examine the technology headlines that caught our attention toward the end of the year, including net neutrality, the data hack at Uber, some misbehaving drones and what might be on the menu for 2018.
In this episode of “The Dave & Dave Show,” we talk about the debut of the world’s first ETF powered by artificial intelligence (AI). We discuss the technology behind it, if it impacts a fund’s expense ratio and, most importantly, how it’s performing.
The iPhone X has put a renewed spotlight on facial recognition technology. Dave Katz gives us a history on this type of technology, some of the privacy and security issues, what the market looks like and which companies are leading the charge.
In this episode of 'The Dave & Dave Show,' we discuss the technology and financing issues related to the possible return of supersonic air travel. What does today’s market look like for supersonic air travel and can start-ups navigate the many challenges?
Will the robot vacuum collect customer household data and offer it to technology companies to enhance internet of things devices? Here is what information is being collected, potential data privacy and security issues, and iRobot’s response to consumer concerns.
In this episode of the Dave & Dave Show, EisnerAmper Senior Audit Manager Dave Katz tells us about electric car company Tesla receiving a significant investment from Chinese technology giant Tencent.
Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, discusses recent mergers and acquisitions in e-commerce including Amazon's recent acquisition of Souq, a Dubai based e-commerce company.
With tech jobs are estimated to double over the next decade, this episode of the Dave and Dave show, as part of EisnerAmper’s Technology Podcast, discusses the market for tech talent and what the forecast for tech employment looks like.
Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, and Richard Colloca, Partner-in-Charge of EisnerAmper’s Food and Beverage Group, discuss Amazon’s plan to use 'Just Walk Out Technology.'
David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, gives a “state of the union” on self-driving cars, an overview of Uber’s unique experiment in Pittsburgh, and a glimpse of what we can expect in the marketplace.
In this episode of the Dave & Dave Show, Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, tells us about this space-age technology that could revolutionize personal travel and commercial traffic.
David Katz, Senior Audit Manager in EisnerAmper's Technology and Life Sciences Practice, discusses the commercial drone market, including potential markets, barriers to entry and where capital investment is headed.
David Katz, Senior Audit Manager in EisnerAmper's Technology and Life Sciences Practice, discusses some of the financial aspects of virtual reality, such as investment, valuation, revenue recognition and more.